Topics

Startup Icosavax gains $51M from funding round

05:51 EDT 4 Oct 2019 | SmartBrief

Icosavax, which is developing a respiratory syncytial virus vaccine, has gained $51 million from a financing round that will  -More

Original Article: Startup Icosavax gains $51M from funding round

NEXT ARTICLE

More From BioPortfolio on "Startup Icosavax gains $51M from funding round"

Quick Search

Relevant Topic

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...